Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propofol target-controlled infusion with different doses of esketamine in radical thyroid cancer surgery
ChiCTR2100046368Phase 4Recruiting
- Sponsor
- Liaoning Province Cancer Hospital
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of esketamine and propofol in thyroid cancer (3 arms), sponsored by Liaoning Province Cancer Hospital. Primary endpoint: VAS score. Started May 2021; status: recruiting.
02
Drugs
esketaminepropofol
03
Conditions
thyroid cancer
Beyond the preview
Go deeper on ChiCTR2100046368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046368.